【AI Explained】Liquid biopsies across the cancer care continuum.

Literature Information

TL;DR

This study emphasizes the transformative potential of liquid biopsies, particularly through the analysis of circulating cell-free DNA (cfDNA), in enhancing cancer detection and monitoring in precision oncology. It identifies current technical and clinical challenges that hinder their widespread adoption, advocating for improvements in detection sensitivity and assay accessibility to facilitate their integration into clinical decision-making for better cancer care.

Search for more papers on MaltSci.com

Liquid biopsy · circulating cell-free DNA · precision oncology · clinical sensitivity · therapeutic decision-making

Abstract

Liquid biopsies have the potential to transform precision oncology by enabling the sensitive and timely detection of cancer across various clinical settings. Minimally invasive analyses of circulating cell-free DNA (cfDNA) have emerged as cutting-edge approaches for cancer detection, characterization and monitoring. Early efforts focused on mutation-based targeted sequencing, whereas newer methods use whole-genome and epigenome sequencing combined with artificial intelligence to broaden the range of alterations that can be assessed in cfDNA. Despite these advances, substantial technical and clinical challenges prevent widespread adoption. Key areas for improvement include achieving clinically meaningful detection sensitivities, enhancing assay accessibility and prospectively evaluating the clinical sensitivity of circulating tumor DNA burden in early and metastatic settings, to support the integration of liquid biopsies into therapeutic decision-making. Here we discuss technologies and analytical methodologies in cfDNA detection, together with their clinical validity and utility. We highlight opportunities to address key challenges and to support the implementation of liquid biopsies throughout the cancer care continuum.

MaltSci.com AI Research Service

Primary Questions Addressed

1. What are the specific technical challenges that currently limit the adoption of liquid biopsies in clinical practice?
2. How do different sequencing technologies impact the sensitivity and specificity of cfDNA detection in various cancer types?
3. In what ways can artificial intelligence enhance the analysis of cfDNA for more accurate cancer characterization?
4. What are the implications of integrating liquid biopsies into therapeutic decision-making for early versus metastatic cancer patients?
5. How can prospective evaluations of circulating tumor DNA burden inform treatment strategies and patient outcomes in oncology?

Key Findings

Research Theme and Scope

The review focuses on the emerging field of liquid biopsies, particularly the analysis of circulating cell-free DNA (cfDNA), as a transformative approach in precision oncology. It aims to provide insights into the technological advancements, clinical applications, and challenges associated with cfDNA in cancer detection, characterization, and monitoring.

Main Findings and Perspectives

• Technological Advances: Initial methods for cfDNA analysis primarily relied on mutation-based targeted sequencing. Recent innovations have expanded to include whole-genome and epigenome sequencing, often enhanced by artificial intelligence, which allows for a broader assessment of genetic alterations in cfDNA.
• Clinical Applications: Liquid biopsies have the potential to facilitate early cancer detection, monitor treatment response, and provide insights into tumor evolution. They can be particularly beneficial in settings where traditional biopsies are challenging.
• Challenges: Despite the promise of liquid biopsies, several technical and clinical hurdles remain, including:
  • Achieving clinically relevant detection sensitivities.
  • Ensuring assay accessibility for routine clinical use.
  • Conducting prospective evaluations of the clinical sensitivity of circulating tumor DNA (ctDNA) in both early and metastatic cancer settings.

Research Progress

• Technological Development: The transition from targeted sequencing to more comprehensive genomic analyses marks a significant milestone in cfDNA research. The integration of artificial intelligence in data interpretation enhances the capability to detect subtle genomic alterations.
• Clinical Validity: Ongoing studies are crucial to establish the clinical validity of cfDNA assays. These studies aim to correlate cfDNA findings with clinical outcomes, thus supporting the utility of liquid biopsies in therapeutic decision-making.

Controversies and Limitations

• Detection Sensitivity: There is ongoing debate regarding the sensitivity of current cfDNA assays, particularly in early-stage cancers where ctDNA levels may be low.
• Accessibility: The cost and complexity of advanced sequencing technologies can limit accessibility, particularly in resource-limited settings.
• Standardization: The lack of standardized protocols for cfDNA extraction, analysis, and interpretation presents a barrier to widespread adoption in clinical practice.

Future Research Directions

• Improving Sensitivity and Specificity: Future studies should focus on enhancing the sensitivity and specificity of cfDNA detection methods, particularly for early-stage cancers.
• Clinical Integration: Research should explore how liquid biopsies can be effectively integrated into clinical workflows and decision-making processes, including treatment selection and monitoring.
• Longitudinal Studies: Long-term studies are needed to assess the prognostic value of cfDNA dynamics over the course of treatment and disease progression.

Conclusion

Liquid biopsies represent a promising frontier in precision oncology, offering minimally invasive methods for cancer detection and monitoring. While significant advancements have been made in cfDNA analysis technologies, challenges related to sensitivity, accessibility, and standardization must be addressed to fully realize their potential in clinical practice. Continued research and innovation in this field are essential to support the integration of liquid biopsies into the cancer care continuum.

References

1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. - Freddie Bray;Mathieu Laversanne;Hyuna Sung;Jacques Ferlay;Rebecca L Siegel;Isabelle Soerjomataram;Ahmedin Jemal - CA: a cancer journal for clinicians (2024)
2. Cancer statistics, 2025. - Rebecca L Siegel;Tyler B Kratzer;Angela N Giaquinto;Hyuna Sung;Ahmedin Jemal - CA: a cancer journal for clinicians (2025)
3. Early detection of cancer. - David Crosby;Sangeeta Bhatia;Kevin M Brindle;Lisa M Coussens;Caroline Dive;Mark Emberton;Sadik Esener;Rebecca C Fitzgerald;Sanjiv S Gambhir;Peter Kuhn;Timothy R Rebbeck;Shankar Balasubramanian - Science (New York, N.Y.) (2022)
4. Origins, structures, and functions of circulating DNA in oncology. - A R Thierry;S El Messaoudi;P B Gahan;P Anker;M Stroun - Cancer metastasis reviews (2016)
5. The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. - Zijian Hu;Honghong Chen;Yanzhu Long;Ping Li;Yueqing Gu - Critical reviews in oncology/hematology (2021)
6. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. - Yanni Y N Lui;Ki-Wai Chik;Rossa W K Chiu;Cheong-Yip Ho;Christopher W K Lam;Y M Dennis Lo - Clinical chemistry (2002)
7. Genome-wide cell-free DNA fragmentation in patients with cancer. - Stephen Cristiano;Alessandro Leal;Jillian Phallen;Jacob Fiksel;Vilmos Adleff;Daniel C Bruhm;Sarah Østrup Jensen;Jamie E Medina;Carolyn Hruban;James R White;Doreen N Palsgrove;Noushin Niknafs;Valsamo Anagnostou;Patrick Forde;Jarushka Naidoo;Kristen Marrone;Julie Brahmer;Brian D Woodward;Hatim Husain;Karlijn L van Rooijen;Mai-Britt Worm Ørntoft;Anders Husted Madsen;Cornelis J H van de Velde;Marcel Verheij;Annemieke Cats;Cornelis J A Punt;Geraldine R Vink;Nicole C T van Grieken;Miriam Koopman;Remond J A Fijneman;Julia S Johansen;Hans Jørgen Nielsen;Gerrit A Meijer;Claus Lindbjerg Andersen;Robert B Scharpf;Victor E Velculescu - Nature (2019)
8. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. - Matthew W Snyder;Martin Kircher;Andrew J Hill;Riza M Daza;Jay Shendure - Cell (2016)
9. Inferring expressed genes by whole-genome sequencing of plasma DNA. - Peter Ulz;Gerhard G Thallinger;Martina Auer;Ricarda Graf;Karl Kashofer;Stephan W Jahn;Luca Abete;Gunda Pristauz;Edgar Petru;Jochen B Geigl;Ellen Heitzer;Michael R Speicher - Nature genetics (2016)
10. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. - Rebecca J Leary;Mark Sausen;Isaac Kinde;Nickolas Papadopoulos;John D Carpten;David Craig;Joyce O’Shaughnessy;Kenneth W Kinzler;Giovanni Parmigiani;Bert Vogelstein;Luis A Diaz;Victor E Velculescu - Science translational medicine (2012)

© 2025 MaltSci - We reshape scientific research with AI technology